Verona pharma announces analyses demonstrating ensifentrine reduced exacerbation rates across subgroups in phase 3 enhance-2 trial for copd

London and raleigh, n.c., oct. 14, 2022 (globe newswire) -- verona pharma plc (nasdaq: vrna) (“verona pharma” or the “company”), announces additional exacerbation* subgroup analyses from the phase 3 enhance-2 (“ensifentrine as a novel inhaled nebulized copd therapy”) trial in chronic obstructive pulmonary disease (“copd”). top-line results from the trial are available on verona pharma's website here.
VRNA Ratings Summary
VRNA Quant Ranking